ZBTB17

Across TCGA pan-cancer cohorts, ZBTB17 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB17 data layer compared with 17 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ZBTB17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBTB17 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, PDAC, and GBM are the cancer types where ZBTB17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	1.000	0.419	.008	19	view →
PDAC	DFS	Quartile	All	0.204	0.393	.036	5	view →
GBM	OS	Median	All	0.906	0.894	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZBTB17–LSCC (DFS)

Open the LSCC breakdown →